• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PNVL3.SA
Share

Dimed S.A. Distribuidora de Medicamentos Stocks

R$ 11.25Last Updated 14.08.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

R$ 355.97M

R$ 11.25
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Eldorado do Sul, Brazil, Dimed S.A. Distribuidora de Medicamentos is a Brazilian company that supplies a wide range of goods, including pharmaceuticals, fragrances, personal care products, cosmetics, and dermocosmetics. Its business model encompasses both retail and wholesale operations. The company distributes its merchandise through logistical hubs situated in the states of Rio Grande do Sul, Paraná, and Espírito Santo. Furthermore, it boasts an extensive retail network of 517 stores, located across Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo. Before April 2000, the company was known as Panvel S.A. Drogarias e Farmacias.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, undervalued on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PNVL3.SA is 17.8 and suggests 58.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.08.2026 21:00

Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16

16.08.2026 15:01

A Problem Worth Billions: How Much Is the EU Stock Market Losing Due to Mental Health Disorders?

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026